VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Oriental Land Co., Ltd. vs Bristol-Myers Squibb Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Oriental Land Co., Ltd.
4661 · Tokyo Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Oriental Land Co., Ltd.'s moat claims, evidence, and risks.
View 4661 analysisBristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisComparison highlights
- Moat score gap: Oriental Land Co., Ltd. leads (95 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Oriental Land Co., Ltd. has 3 segments (81.3% in Theme Park Segment); Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)).
- Primary market structure: Duopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Oriental Land Co., Ltd. has 5 moat types across 4 domains; Bristol-Myers Squibb Company has 4 across 3.
Primary market context
Oriental Land Co., Ltd.
Theme Park Segment
Large-scale destination theme parks in Japan (Tokyo Disney Resort parks: Tokyo Disneyland and Tokyo DisneySea)
Japan (with inbound tourism)
Consumers (domestic residents and inbound tourists), plus group/agency channels
Owner/operator of theme parks under licensed IP
81.3%
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Side-by-side metrics
Moat coverage
Shared moat types
Oriental Land Co., Ltd. strengths
Bristol-Myers Squibb Company strengths
Segment mix
Oriental Land Co., Ltd. segments
Full profile >Theme Park Segment
Duopoly
Hotel Business Segment
Oligopoly
Other Business Segment
Competitive
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.